Evoke Pharma, a gastrointestinal-focused pharmaceutical company, said that GIMOTI data would be presented at the American College of Gastroenterology annual meeting in October 2023. GIMOTI is a metoclopramide nasal spray formulation that is approved to treat diabetic gastroparesis symptoms. According to the statistics to be provided, GIMOTI can significantly reduce healthcare costs when compared to the current standard of care for oral metoclopramide. As a nasal spray, GIMOTI avoids the many absorption difficulties that diabetic gastroparesis patients typically experience with oral medications. The findings presented here add to previous research demonstrating that GIMOTI reduces healthcare utilization, such as ER visits and hospitalizations. According to experts, GIMOTI has the potential to lower total healthcare expenses.

To know more: About the original article click here.